Deal-Making

Samsung Biologics to manufacture Kineta’s antibody immunotherapy

Korean CDMO Samsung Biologics will develop and provide manufacturing services to support IND filing for Kineta’s anti-VISTA antibody candidate. Contract development manufacturing organization (CDMO) Samsung Biologics has signed a partnership agreement to provide end-to-end services for Kineta’s anti-V-domain immunoglobulin suppressor of T cell activation (anti-VISTA) candidate KVA12.1, which aims to treat solid tumors. Preclinical studies have shown KVA12.1 to have single agent anti-tumor activity and that targeting VISTA along with programmed cell death-1 (PD-1), PD ligand 1 (PD-L1), or cytotoxic…

Second Bluebird gene therapy approval a boon for Minaris

CDMO Minaris says it will be the commercial manufacturer for Skysona (elivaldogene autotemcel, Lenti-D), a second Bluebird Bio gene therapy approved by the European Commission. The European Commission (EC) granted marketing authorization of Skysona for the treatment of early cerebral adrenoleukodystrophy (CALD) yesterday. The one-time gene therapy uses a patient’s own hematopoietic stem cells (HSC) to treat the underlying cause of the neurologic condition CALD. SKYSONA uses ex vivo transduction with the Lenti-D lentiviral vector (LVV) to add functional copies…

BioNTech adds Kite’s T cell platform and production facility

BioNTech ups its production capacity to support cell therapy clinical trials by acquiring Kite’s R&D platform and gaining a facility in Gaithersburg, Maryland. The deal, of which financial details have not been disclosed, sees BioNTech acquire Gilead Sciences’ Kite Pharma’s solid tumor neoantigen T cell receptor (TCR) R&D technology. The deal will also see BioNTech take over the lease at the Gaithersburg manufacturing facility. BioNTech became a household name after BNT162b2 became the first messenger RNA (mRNA) COVID-19 vaccine to…

Forge Bio wins GentiBio AAV vector contract

Forge Bio will develop and manufacture adeno-associated viral (AAV) vectors for GentiBio’s engineered Tregs candidates from its site in Columbus, Ohio. The deal will see contract development and manufacturing organization (CDMO) Forge Bio use its Blaze Vector production platform and HEK 293 Suspension Ignition Cells to support GentiBio’s preclinical and clinical programs. The work will be undertaken at Forge Bio’s facilities at The Hearth, Columbus, which has grown through heavy investment over the past year. “Forge has rapidly expanded our…

Rebranded AMRI on spending spree with LakePharma and Integrity buys

A new name, the purchase of biomanufacturer LakePharma, and the addition of fill-finish firm Integrity Bio. All in a week’s work for Curia, the CDMO previously known as AMRI. Contract development and manufacturing organization (CDMO) AMRI rebranded itself this week as Curia before announcing a double acquisition expected to boost its capacity and capabilities in the manufacturing services space. The first deal sees the CDMO acquire Integrity Bio, a privately held formulation and fill-finish organization headquartered in Camarillo, California. Financials…

Poseida joins Cellares’ early-access cell therapy tech program

Cellares Corporation has added a third firm to its early-stage partnership program, giving Poseida Therapeutics access to its closed and automated cell therapy manufacturing platform. Californian firm Cellares is looking to overcome limitations in current advanced therapy manufacturing through the development of its manufacturing platform, the Cell Shuttle. The Cell Shuttle is a modular and automated solution comprising hardware, software, robotics and consumables and according to the firm is capable of producing 10 patient doses simultaneously. Since 2020, the firm…

Selexis and KBI to advance Immatics program towards IND

Selexis and KBI will provide integrated services to develop Immatics’ bispecific T cell engaging receptor program. Selexis will leverage its SUREtechnology to produce a clonal cell line for Immatics’ candidate IMA402 and KBI Biopharma will utilize its formulation, analytics, and manufacturing capabilities. No financial details have been disclosed. “Selexis and KBI are both JSR Life Sciences companies and are able offer partners integrated services that can accelerate biologic development timelines,” CEO of both companies Dirk Lange told BioProcess Insider. “These…

Batavia collaborates with Swiss start-up to deliver COVID-19 vaccine

Batavia Biosciences will use its HIP-Vax manufacturing technology to develop and deliver 1000 doses of RocketVax’s second generation COVID-19 vaccine candidate.   The deal, of which financial details have not been disclosed, sees Batavia develop the clinical process to deliver RocketVax’s (a subsidiary of Swiss Rockets AG) COVID-19 vaccine candidate RVX-13. RVX-13 does not use a single COVID-19 derived antigen but instead compromises all major immunogenic features of the COVID-19 virus. In turn, this aims to increase vaccine efficacy and…

Cytiva doubles liquid cell culture media capacity with Intermountain bolt-on

The latest acquisition by Cytiva sees it add Intermountain Life Sciences, gaining a buffer and cell culture media manufacturing site in Utah. Terms of the deal have not been disclosed, but Danaher Corporation subsidiary Cytiva has added a 25,000+ square-foot facility in Salt Lake City, Utah. The site can produce 60,000 L/day of Water for Injection (WFI) and formulation lot sizes to 14,000 L, and will significantly expand Cytiva’s bioprocessing offering, said Olivier Loeillot, VP of Cytiva. “This acquisition is…

Ins & Outs: CureVac exec shake up following low COVID-19 vaccine efficacy

After reporting low efficacy results for its COVID-19 vaccine candidate, CureVac has appointed a new chief operating officer and made other changes in leadership. Sit back, relax, and enjoy BioProcess Insider’s Ins & Outs. CureVac entered the COVID-19 vaccine race in March 2020 when the German biotech received $88 million from the European Commission to expedite construction of a plant set to make a potential mRNA vaccine against coronavirus. In August 2020 with $213 million in IPO cash to fund the human…